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Abstract The pharmaceutical industry manufactures 
products of the highest importance to society. Keeping 
the cost of the production of medicines at low levels is 
very important to ensure better accessibility to medicines, 
especially if we think of the less wealthy countries of the 
planet. Among the production steps that need to be 
carefully monitored and optimized, the final packaging 
phase is sometimes considered less important. This is a 
mistake, because, being the last stage of production, it can 
negatively affect all other upstream phases. The aim of 
this work is to evaluate whether the throughput and 
work in process diagrams can be useful for the rapid and 
effective control of the line activity. The result was 
positive, given that, with the help of a case study, we 
could identify four patterns corresponding to the same 
number of typical operating conditions of the line, either 
regular or altered. After identifying the typical pattern of 
the line studied, the use of such diagrams can be 
employed either in real-time or retrospectively for an 
accurate analysis of the behaviour of the production line. 
 
Keywords Performance Improvement, Pharmaceutical 
Packaging Line, Throughput Diagram, Buffer Level 
1. Introduction  
 
The pharmaceutical industry is one of the world’s most 
important production sectors. First of all, its importance 
is related to the category of such products: drugs, in fact, 
are essential to attend, to prevent and to alleviate the 
effects of the bulk of the syndromes that can damage 
people, thus contributing to keeping good health. 
 
Nowadays, drugs are widespread in most industrialized 
countries, though they are not yet equally available in 
developing ones. 
 
The unavailability of drugs for the poorest has many 
causes: the unavailability of suitable human, technical 
and financial resources; the low purchasing power of the 
Third World; the running out of production of non-
fruitful drugs, their use only for the diseases of 
developing countries [1], etc. 
 
This situation occurs even though the World Health 
Organization (WHO), which is the association dealing 
with international public health, has defined a list of 
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essential medicines that should be available everyone 
around the world. The last updated list was drawn up 
around one year ago, in April 2013 [2]. 
 
The manufacture of products with high social impact is 
only one of two sides of the coin of pharmaceutical firms. 
On the other hand, significantly, they are firms, with all 
the features related to a productive background and, 
notably, the necessity to have a profit margin. 
 
According to the Boston Consulting Group [3], the 
pharmaceutical industry is one of the world’s most 
profitable businesses, most obviously because its 
products have a high added value per mass unit [4]. We 
can consider the example of the bio-pharmaceutical firm 
Pharmacyclics [3]: during the period from 2008 to 2012, 
its average total shareholder return was about 109%. 
 
The attainment of a high profit in this industry is, 
however, quite difficult to achieve and maintain over 
time. For this reason, it is very important to apply 
specific strategies to have a strong, competitive 
advantage. 
 
The reasons for this complexity are related to the 
specific structure of the pharmaceutical industry, 
comprising patents, huge investments, and long lead 
times and product pipelines. Drugs production, in fact, 
has several different phases, the first of which, research 
[5], entails huge financial, human and time investments. 
Furthermore, only a small percentage of the new 
substances identified during the research phase as a 
final point becomes a real drug. 
 
After a new drug’s discovery and development, we have 
the production phase. Production control is extremely 
important, since it affects the profitability of the entire 
process. This is why a great deal of attention must be 
given to effectiveness and efficiency, using theoretical 
approaches or more complex simulation strategies. 
 
After manufacturing activities, the packaging phase 
takes place. Packaging activity represents a direct link 
between production and sales [6], essential for the 
commercialization of products to final consumers. 
Even though it is the last activity of the production 
chain, packaging elements might be considered during 
the first phases of the manufacturing process and 
development. In fact, it is an essential and central part 
in the retail and commercialization of products, and a 
key point in the marketing mix definition. Good 
packaging management, moreover, requires a deep 
knowledge of operations management and operations 
research [7]. Packaging lines need to be deeply 
analysed as well as other production systems, along 
with complex approaches like simulation [8]. 
The packaging of a product is strictly related to its 
appearance for potential customers: this element, in fact, 
can be an important factor in the choice of one product 
compared to its competitors. 
 
In the pharmaceutical sector, however, the appearance of 
a product is less important than in the many sectors. The 
majority of drugs, in fact, are prescribed by doctors based 
on their active principles. Over-the-counter drugs, on the 
other hand, are chosen by patients personally in relation 
to usual utilization, to the producer pharmaceutical firm, 
to possible allergies and also – perhaps - to their 
packaging. 
 
The package provides protection for products [9], which 
is essential to retailing, carriage and selling activities. This 
function is crucial for fragile products, for example, drugs 
requiring a specific temperature for conservation and 
transportation. 
 
For pharmaceutical products’ commercialization, the 
package of the final products can perform several 
functions [10], such as: 
• Containment: this is the main function required of 
the drug package; it could be appropriate to drug 
features, manufacturing and transportation 
necessities. 
• Protection: the package must protect medicines 
from the external environment and all possible 
contamination factors [11], like light, dust and 
biological substances, etc. 
• Preservation and information: looking at the 
package, consumers must be able to obtain all the 
main information about the product they want to 
buy. 
• Identification: the package must allow the customer 
to identify and distinguish a product from any 
competitors. 
• Convenience: for some kinds of medicines, it is 
essential that the product should have a package of 
suitable size (the size of eye drops, for example, is 
designed for the need to use the product within a 
few days of opening the package). 
 
The material used is another important element in 
packaging activities, since it must be suitable to 
contain substances for inhaling, eating and injections, 
etc. In recent years, the way in which drugs are used 
has changed a lot, in favour of inhaling and 
transdermal giving. These have caused significant 
improvement in packaging activities: the generation of 
solutions to the customer’s specification is now ever 
more widespread [10]. 
 
In the pharmaceutical sector, there are several kinds of 
packages that are chosen according to aspects such as the 
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type of drug (pills, cream, inhaling drugs, etc.), the kind 
of patient (children, adults, old men, etc.) and the 
reference market (who administers drugs, whether a 
doctor or the patient) [10]. The blister pack is the most 
common package type for solid drugs. Its use is 
widespread in Europe, while it is also diffusing gradually 
in the USA [12] (to the detriment of glass bottles). The 
choice of blister is related to several aspects, and first of 
all to the certainty of having an intact product, from 
manufacture to final consumer: to sabotage a blister, in 
fact, breaking is essential. Moreover, the contamination of 
an undamaged blister is rather dubious [12]. During 
packaging and retailing, damage to glass bottles is 
avoided. There are advantages also for consumers, which 
can better control the advised dosage in a portable 
package.  
 
From the above, it stands to reason that each phase of a 
new drug manufacturing process - from research to the 
packaging phase - is essential to achieving an inside track 
on the competition. 
 
Considering the difficulty to achieve and maintain high 
profit margins in the pharmaceutical industry (because of 
the specific features of products and markets), it is 
essential to optimize each phase of the supply chain (SC) 
[13]. In the literature, there are many papers concerning 
this specific topic [4] [13] [14] [15]: Rotstein et al. (1999) 
[15] were the first to deal with this subject [13], presenting 
an optimization model about research phase problems, 
capacity planning and investment strategies. 
Papageorgiou et al. [16] improved the model with 
additional information about the manufacturing process 
and the firm’s structure. Supply chain optimization 
models for the pharmaceutical industry have also been 
used for the identification of the optimal outsourcing 
level [17] to maximize profit.  
 
Supply chain optimization in a pharmaceutical firm 
requires both the careful design of its activities and the 
continuous monitoring of them. Manufacturing and 
logistic phases, for example, are critical in a SC, and so 
they are often supervised. Layout design [18], 
productivity improvement [19], effectiveness and 
efficiency are some of the most important parameters in 
promptly identifying critical situations and operating in 
order to eliminate them. The a posteriori analysis of 
manufacturing and retail process data is also useful to 
planning some improvement actions. 
 
The possibility of controlling the operating phases of a 
multi-stage manufacturing process is essential in order to 
describe the processes and to identify all the undesirable 
situations. Production control is an optimization problem 
concerning the definition of when, and how much, to 
produce [20]. It has two aims, namely customer 
satisfaction (satisfying demands as quickly as possible) 
and low in-process inventories [21]. 
 
They are usually classified into push-type systems and 
pull-type systems [22]. Push control systems are based on 
systems which consider the available information to 
predict future customer demand. Pull control systems, on 
the other hand, are based on considering requests for 
finished parts as a trigger to produce. Pull production 
control is applied in between stages that form the 
production system. Each stage contains a manufacturing 
process (with the work in progress of the stage) and an 
output buffer (it contains the finished parts of the stage 
itself) [23]. Therefore there is a material flow from the 
upstream to the downstream stages which is caused by a 
flow of demands moving from the downstream to the 
upstream stages. The release of parts into each stage, in 
fact, is associated with the arrival of customer demand for 
final products [21].  
 
The most well-known pull control systems are the kanban 
control system (KCS) and the base stock control system 
(BSCS). The KCS is based on kanban, which is a 
production authorization card: demand is forwarded 
upstream from a generic stage (i) to the previous stage (i-
1) only when the parts of the stage i itself flow 
downstream to the next stage (i+1). For this reason, the 
KCS restricts the maximal level of WIP and finished parts 
of a stage [24]. The BSCS, on the other hand, does not 
allow limiting WIP but is very reactive since, when an 
external demand arrives, it is immediately transmitted to 
all the stages of the system. The BSCS tries to maintain a 
target inventory of finished parts, called a ‘base stock’ 
[20]. 
 
These production control systems are very interesting but 
they are not suitable for high productivity production 
lines, which can be considered to be a single, very 
complex machine, and for which other appropriate tools 
are used. Very interestingly, in these cases, are methods 
of load-oriented manufacturing control, which are 
designed to limit and balance the WIP at the lowest level 
possible for the high utilization of work centres and the 
rapid flow of orders. This methodology, developed since 
the 1980s [25] [26], is particularly useful in production 
environments where the dynamic variation of the 
quantities involved causes effects which are very complex 
to manage with traditional static approaches. 
 
This paper, in particular, inspects the use of production 
diagrams - above all the throughput diagram and the 
buffer level diagram - as a tool to identify production 
inefficiencies in a pharmaceutical packaging line. The aim 
of the study is to demonstrate the possibility of detecting 
causes of loss of performance thanks to simple 
instruments. 
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